Kornimate/medical-research-clean huggingface dataset:
promoting smoking cessation in lung cancer screening through proactive treatment

Conditions: Smoking Reduction; Tobacco Use; Tobacco Smoking; Tomography; Lung Diseases; Lung Neoplasms

Summary: this pragmatic trial will evaluate the value of routinely providing proactive smoking cessation support to current smokers as a part of participating in lung cancer screening within veterans health administration.

this trial is a pragmatic randomized trial targeting the care of current smokers who are participating in lung cancer screening at two va sites. primary care providers at these sites will be randomized, and half will be offered tools to help integrate proactive smoking cessation support into the lung cancer screening process. key proactive elements include proactive telephone outreach to all current smokers by a va quitline counselor that follows mailed results letters, and providing providers guidance in offering proactive cessation medication support as part of the lung cancer screening process.

Eligibility criteria:
inclusion criteria: * providers who schedule patients for a lung cancer screening at either of the two va sites. * patients who participate in lung cancer screening and are current smokers at the time of scheduling their screening exam. exclusion criteria: * providers who currently systematically prescribe cessation support medication to all current smokers will be excluded. * patients with urgent findings requiring biopsy/immediate attention on the screening ct will be excluded. * patients with a prior diagnosis of lung cancer or who are receiving active therapy for any cancer, except skin cancer, will be excluded. * patients previously diagnosed with cognitive impairment, dementia, or severe behavioral disorders, or have an indication in chart review of difficulty communicating or participating in telephone counseling sessions will be excluded.

Keywords: smoking cessation lung cancer screening telephone counseling quitline
patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer

Conditions: Ovarian Cancer

Summary: to compare patient outcomes following interval and delayed cytoreductive surgeries and no surgery (neoadjuvant chemotherapy alone) and international variations in access to cytoreductive surgeries in women with advanced stage ovarian cancer.

standard of care in patients with advanced ovarian cancer is primary cytoreductive surgery followed by chemotherapy. neoadjuvant chemotherapy and interval cytoreductive surgery is an alternative in selected patients. most data exist with interval cytoreductive surgery following 3-4 cycles of chemotherapy, however, some patients experience a delay. so far, the impact of delayed cytoreductive surgery (following \>5 cycles of chemotherapy) on patient outcomes is poorly defined. there is also a paucity of data in women who undergo no surgery (\>5 cycles of chemotherapy alone) and factors influencing international discrepancies in access to cytoreductive surgery.

Eligibility criteria:
inclusion criteria: women with stage iii-iv ovarian cancer, undergoing interval (after 3-4 cycles of chemotherapy) or delayed (\>5 cycles of chemotherapy) cytoreductive surgeries or no cytoreductive surgery (\>5 cycles of chemotherapy alone. exclusion criteria: women undergoing recurrent cytoreductive surgery.

Keywords: survival morbidity cytoreduction disparities
dexamethasone for ipack block with acb in total knee arthroplasty

Conditions: Knee Osteoarthritis; Knee Pain Chronic; Knee Arthritis

Summary: effect of adding dexamethasone to infiltration between the popliteal artery and capsule of the knee block with acb in patients undergoing total knee arthroplasty

knee arthroplasty is one of the most common orthopaedic procedures, especially in elderly patients, due to the deformation of joints. patients may complain of severe pain due to surgical trauma and prostheses. regional anaesthesia methods may be performed to reduce the inflammatory response, opioid consumption, and opioid-related side effects.

Eligibility criteria:
inclusion criteria: * patients scheduled for total hip arthroplasty * patients aged \>65 and \<100 years * patients able to provide informed consent * patients able to reliably report symptoms to the research team exclusion criteria: * inability to provide first-party consent due to cognitive impairment or a language barrier
a case-control study of the association between heavy mental and children with attention deficit hyperactivity disorder in korea

Conditions: Attention Deficit Hyperactivity Disorder

Summary: heavy metal has been reported that it can cause attention deficit and behavioral disturbance. the investigators hypothesis is that heavy metal is associated with children with attention deficit/hyperactivity disorder(adhd).


Eligibility criteria:
inclusion criteria: * subjects must meet dsm-iv criteria for adhd based-on the k-schedule for affective disorder and schizophrenia(k-sads-pl-k) interview * subjects signed a written consent form voluntarily. * patient 's assent to participate in the study and written informed consent form signed by one of the parents, parent surrogates, or legal guardian. * subjects/parents, parent surrogates or legal guardian who can understand the participation of the study and voluntarily withdraw from the study at any time exclusion criteria: * subjects who have any history of bipolar disorder, psychotic disorder, and substance use disorder, have been diagnosed with a pervasive developmental disorder, organic brain disease and seizure disorder. * subjects who have significant suicidal ideation or homicidal ideation * subjects with mental retardation * subjects with tourette's syndrome requiring drug therapy. * subjects who currently have a significant medical conditions (e.g. diseases of cardiovascular, hepatic, renal, respiratory, glaucoma). * subjects who have abnormalities in the ecg or show clinically significant abnormalities of laboratory results, including serum chemistries and hematology. * subjects who have been administrated alpha-2 adrenergic receptor agonist,antidepressant, antipsychotic, benzodiazepines, modafinil, anticonvulsant within recent 2 months. * subjects who dyed their hair within 8 weeks
the women's health study: from adolescence to adulthood

Conditions: Pelvic Pain; Endometriosis; Dysmenorrhea; Infertility

Summary: in order to learn more about women's health issues that occur over the lifespan, the women's health study: from adolescence to adulthood is building a biorepository and database. the biorepository collects, processes and stores samples (such as urine, saliva, blood, cells, tissue and peritoneal fluid) until they are needed for research. the database contains de-identified information about our study participants. the biorepository and database are being created to serve as a resource for researchers from boston children's hospital, brigham and women's hospital and outside institutions.


Eligibility criteria:
inclusion criteria: * female * at least 7 years old * not experiencing natural menopause exclusion criteria: -

Keywords: endometriosis dysmenorrhea pelvic pain women's health adolescence biorepository observational women female gynecology fertility infertility
gastrointestinal tolerability study of dimethyl fumarate in participants with relapsing-remitting multiple sclerosis in germany

Conditions: Relapsing-Remitting Multiple Sclerosis

Summary: the primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal-related events reported by participants with relapsing-remitting multiple sclerosis initiating therapy with bg00012 (dimethyl fumarate, dmf) in the clinical practice setting. the secondary objectives of this study in this study population are as follows: to evaluate gastrointestinal-related events requiring symptomatic therapy and the role of those therapies over time; to evaluate gastrointestinal-related events that lead to a physician's decision to manage the events with bg00012 dose modification; and to evaluate gastrointestinal-related events that lead to bg00012 discontinuation after the use of symptomatic therapy.


Eligibility criteria:
key inclusion criteria: * have a confirmed diagnosis of relapsing-remitting multiple sclerosis according to the current mcdonald criteria and satisfy the therapeutic indication as described in the official local registration for tecfidera (dimethyl fumarate) * naïve to dimethyl fumarate and fumaric acid esters key exclusion criteria: * female subjects who are currently pregnant or breastfeeding or who are considering becoming pregnant while in the study * history of significant gastrointestinal disease (e.g., irritable bowel disease, peptic ulcer disease, history of major gastrointestinal surgeries), or chronic use of gastrointestinal-related symptomatic therapy as determined by the investigator (or ≥ 7 consecutive days of gastrointestinal-related symptomatic therapy * known active malignancies * history of anaphylaxis or severe allergic reactions or known drug hypersensitivity * current use of b vitamin supplements * in the opinion of the investigator, blood test values suggestive of a low lymphocyte count or renal or hepatic impairment, as described in the product label precautions for use note: other protocol-defined inclusion/exclusion criteria may apply

Keywords: gastrointestinal event
induction of migraine aura with cilostazol

Conditions: Migraine With Aura; Stroke

Summary: in a double blind placebo-controlled cross-over study the effect of cilostazol on aura induction and endothelial response is tested in patient with migraine with aura.

migraine with aura is associated to an increased risk of stroke. the mechanism behind such increased risk is not fully understood. cilostazol induce headache and migraine in migraine patients and is used as secondary prevention of stroke. the effect on aura induction is not known. we investigate the aura inducing potential of cilostazol and associated changes in endothelial function.

Eligibility criteria:
inclusion criteria: * migraine with aura * minimum of 2 attacks/year exclusion criteria: * chronic tension type headache * cardiac arrhythmias
a study on the use of healthcare resources and costs of attention deficit hyperactivity disorder (adhd) in adults in england

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)

Summary: the main aim of the study is to learn about the demographic and clinical characteristics, healthcare resources utilization (hcru) and costs associated with before and after adhd diagnosis in england. no study medicines will be provided to participants in this study. the record available in clinical practice research datalink (cprd) database and hospital episode statistics (hes) database for adhd participants will be assessed.


Eligibility criteria:
inclusion criteria 1. age greater than or equal to (\>=) 18 years at the beginning of the patient observation period (that is 18-months prior to the adult adhd diagnosis to ensure they would have been seen in adult health care services). 2. first record of an adult adhd diagnosis between 01st january 2016 and 30th june 2018. 3. data availability in the database at least during the 18-months before and after the index date. exclusion criteria a participant will be excluded from the study if their cprd linked to hes electronic medical record data includes: 1. incomplete information for key demographics (that is, missing age or sex). 2. clinical history of a diagnosis of adhd during childhood or adolescence. 3. prescription of a licensed adult adhd medication (that is, methylphenidate, lisdexamfetamine, dexamfetamine, atomoxetine) during the pre-index period.
long-term outcomes of superficial esophageal squamous cell carcinoma

Conditions: Esophageal Neoplasms

Summary: tumor is the primary public health problem and the incidence of esophageal cancer showed the increasing trend in the past thirty years. according to the statistics in 2015, the new onset of esophageal cancer is about 477,900 yearly. the mainly pathologic type of esophageal cancer in china is esophageal squamous cell carcinomas, which accounts for more than 90% of patients in china. with the development of endoscopic technics, more and more patients choose to receive the endoscopic procedure rather than traditional surgery. however, the long-term efficacy and outcomes of patients with superficial esophageal squamous cell carcinoma received different interventions remained unclear. thus, investigators aim to conduct a multi-center retrospective study to investigate the long term outcomes of superficial esophageal squamous cell carcinoma patients receiving endoscopic treatment and surgery.


Eligibility criteria:
inclusion criteria: * patients received endoscopic treatment because of the superficial esophageal disease and had the pathologic diagnosis of squamous cell carcinoma. exclusion criteria: * combined with other severe disease * with a history of esophageal surgery * combined with other malignant disease

Keywords: superficial esophageal squamous cell carcinoma efficacy survival
sirolimus in combination with mec in high risk myeloid leukemias

Conditions: Myeloid Leukemias; AML; Leukemia; CML

Summary: the purpose of this study is to evaluate the side effects of sirolimus (rapamycin) given in combination with chemotherapy (mitoxantrone + etoposide + cytarabine (mec)) on high risk myeloid leukemias.


Eligibility criteria:
inclusion criteria: * must have histologic evidence of advanced myeloid leukemias defined as one of the following: primary refractory non-m3 aml; relapsed non-m3 aml; secondary aml; intermediate or poor prognosis de novo aml in patients who are \>= 60 years old * \>= 18 years of age * ecog performance status of 0, 1 * able to consume oral medication * initial laboratory values: creatinine \<= 2.0 mg/dl; total or direct bilirubin \<= 1.5/dl; sgpt(alt) \<= 3xuln; negative pregnancy test for women with child-bearing potential * ejection fraction of \>= 45% exclusion criteria: * subjects with fam b3 * must not be receiving chemotherapy (except hydroxyurea) * not receiving growth factors, except for erythropoietin * subjects with a "currently active" second malignancy other than non-melanoma skin cancers * subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, mi within the last 6 months or uncontrolled cardiac arrhythmia * subjects taking diltiazem * subjects who require hiv protease inhibitors or those with aids-related illnesses * no evidence of cerebellar dysfunction at baseline or during prior cytarabine therapy * not pregnant or breastfeeding * uncontrolled infection * subjects taking carbamazepine, rifabutin, rifampin, rifapentine, st. john's wort, clarithromycin, cyclosporine, diltiazem, erythromycin, telithromycin, verapamil, tacrolimus

Keywords: advanced myeloid leukemias aml leukemia relapsed myeloid leukemias refractory myeloid leukemias mec rapamycin sirolimus
the value of narrow band imaging in stratifying patients for endoscopic resection or surgery

Conditions: Colorectal Neoplasms

Summary: magnification narrow band imaging (nbi) can make accurate evaluation in in predicting of invasive depth of colorectal neoplasia.

nbi could be used in stratifying patients for endoscopic resection or surgery and got an accurate evaluation.

Eligibility criteria:
inclusion criteria: * consecutive patients with more than one lesion ≧6mm exclusion criteria: * patients with chronic inflammatory bowel disease, * advanced cancer, * insufficient bowel preparation, * familial adenomatous polyposis (fap) * lesions ≦ 5mm and submucosal tumor (smt).

Keywords: narrow band imaging（nbi） colorectal lesions predicting histology
hesperidin and bone health in postmenopausal women

Conditions: Osteoporosis, Postmenopausal

Summary: the primary objective of this clinical trial is to test hesperidin with and without calcilock® for bone resorption suppressing effect in postmenopausal women. the secondary objective is the comparison between 41ca technology and classical biomarker to evaluate bone resorption.

subjects will participate in four phases of the study: baseline of 50 days and three intervention phases which include 50 days receiving product followed by 50 days of recovery. the total duration of the study will be 350 days. if participant has not been previously labeled with 41ca, a 150 day period is added to the study. hesperidin (552mg) and calcilock® (amount per day: calcium: 684 mg; phosphorus: 282mg; magnesium: 102mg; zinc: 2.86mg; vitamin c: 20 mg; vitamin k1: 28µg; vitamin d: 1.86µg) will be administered in the form of cookies (biscuit).

Eligibility criteria:
inclusion criteria: * women at least 4 years postmenopausal exclusion criteria: * medications affecting bone resorption

Keywords: hesperidin osteoporosis bone loss
a study assessing the safety and effectiveness of ic2000 and spy fluorescence imaging systems (spy-phi) in the visualization of lymphatic vessels and identification of lymph nodes during sentinel lymph node biopsy in subjects with breast cancer

Conditions: Breast Cancer; Lymph Node Mapping; Sentinel Lymph Node Biopsy

Summary: this is a prospective, open label, multicenter, non-inferiority within-patient study to determine the effectiveness of ic2000 (indocyanine green (icg) for injection) and the spy portable handheld imaging system (spy-phi) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (lns) during lymphatic mapping and sentinel lymph node biopsy (slnb) procedures as confirmed by technitium99m (tc99m) and gamma probe.


Eligibility criteria:
inclusion criteria: 1. be 18 years of age or older 2. subjects with american cancer society clinical stage 0 ductal carcinoma in situ (dcis) (stage 0, tis, n0, m0), ia (t1\*, n0, m0), ib ((t0, n1mi, m0) or t1\*, n1mi, m0)) or stage iia (t0, n1\*\*m0, or t1, n1\*\*, m0 or t2, n0, m0)1 breast cancer undergoing surgery to remove tumor draining lns. where: * tis = ductal carcinoma in situ * t0 = no evidence of primary tumor * t1 = tumor ≤ 20 mm in greatest diameter * t1\* = includes t1mi * t2 = tumor \>20 mm but ≤ 50 mm in greatest diameter * n0 = no regional lymph node metastasisq1' * n1 = metastasis to movable ipsilateral level i, ii axillary lns * n1\*\* = t0 and t1 tumors with nodal micro-metastasis only are excluded from stage iia and are classified stage ib. * mi = micro-metastasis * m0 = disease has not metastasized from stage iia and are classified stage ib. * m0= no evidence of metastasis * mi= micrometastasis 3. subjects with clinically negative nodal status (n0) with or without neoadjuvant chemotherapy 4. subjects with negative metastatic involvement (m0) 5. subjects of child-bearing potential must not be pregnant or lactating and must have a negative pregnancy test at baseline 6. have signed an approved informed consent form for the study 7. be willing to comply with the protocol exclusion criteria: 1. have had prior axillary surgery or ipsilateral radiation in the breast(s) that is planned for the procedure 2. advanced breast cancer subjects with stage iib, iii and iv 3. known allergy or history of adverse reaction to icg, iodine or iodine dyes 4. subjects who have participated in another investigational study within 30 days prior to surgery 5. pregnant or lactating subject 6. subjects who, in the investigator's opinion, have any medical condition that makes the subject a poor candidate for
drug interaction study of filibuvir with methadone among subjects on chronic methadone maintenance

Conditions: Chronic Hepatitis C

Summary: filibuvir, a cyp3a4 inhibitor is being developed for the treatment of chronic hepatitis c infection. given the likelihood of co administration of filibuvir and methadone, this study will evaluate the effect of filibuvir on the pharmacokinetics of r/s methadone.


Eligibility criteria:
inclusion criteria: * males or females, without evidence of infection with hiv,hbv or hcv, who are on chronic methadone maintenance for at least three months and at a stable dose for at least 1 week prior to study start. exclusion criteria: * evidence of chronic diseases including hiv, hbv or hcv. * evidence of acute or chronic liver disease. * treatment with prescription or nonprescription drugs other than methadone within 7 days.

Keywords: drug interaction with methadone.
the inhaled β2-adrenergic receptor agonist for transient tachypnoea of the newborn (the refsal trial)

Conditions: TTN; Respiratory Failure; PPHN

Summary: clinical trial evaluating the efficacy and safety of salbutamol for the treatment of neonates with a gestational age between 32 and 42 weeks with transient tachypnoea of the newborn (ttn).

multicentre, double-blind, phase iii trial will include infants with a gestational age between 32 and 42 weeks and respiratory disorders treated in neonatal intensive care units in poland. infants will be enrolled no later than 24 h after birth and will be randomly assigned (1:1) to receive nebulized salbutamol with ncpap or placebo (nebulized 0.9% nacl) with ncpap. the primary outcome is the percentage of infants with ttn who develop pphn.

Eligibility criteria:
inclusion criteria: 1. gestational age at birth between 32 and 42 weeks. 2. respiratory disorders (tachypnea and expiratory grunting) lasting longer than 15 minutes after birth, or present for at least 15 minutes in the first six hrs of life, or a need for non-invasive respiratory support between birth and six hrs of life. 3. available chest radiographs obtained within six hrs after birth. 4. available parameters of the acid-base balance (blood ph, partial pressure of o2 and co2, base excess) and blood serum ionogram for na+, k+, ca2+ evaluated in the umbilical cord blood sample. exclusion criteria: 1. need for intubation directly after birth or perinatal asphyxia, defined as abnormal acid-base parameters detected in an umbilical cord blood sample (ph \<7.0 or base excess \< -14 mmol/l). 2. multiple apnea-brady that require immediate intubation before a trial of niv 3. age \>24 h. 4. meconium aspiration syndrome. 5. air leak syndrome. 6. congenital heart disease. 7. congenital diaphragmatic hernia. 8. other severe congenital malformations and genetic disorders (diagnosed before and after birth) associated with increased risk of respiratory failure. 9. the need for a surfactant administration immediately after birth, regardless of the method of its administration (respiratory distress syndrome - rds)

Keywords: ttn pphn cpap salbutamol